Bo Langhoff Hønge1, Sanne Jespersen2, Candida Medina3, David da Silva Té3, Zacarias José da Silva4, Sharon R Lewin5, Lars Østergaard6, Alex Lund Laursen6, Henrik Krarup7, Christian Erikstrup8, Christian Wejse9. 1. Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; Department of Infectious Diseases, Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus, Denmark. Electronic address: bohonge@gmail.com. 2. Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; Department of Infectious Diseases, Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus, Denmark. 3. National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau. 4. Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; National Public Health Laboratory, Bissau, Guinea-Bissau. 5. Department of Infectious Diseases, Alfred Hospital and Monash University, Australia; Centre for Biomedical Research, Burnet Institute, Melbourne, Australia. 6. Department of Infectious Diseases, Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus, Denmark. 7. Department of Clinical Biochemistry, Aalborg University Hospital, Denmark. 8. Department of Clinical Immunology, Aarhus University Hospital, Denmark. 9. Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; Department of Infectious Diseases, Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus, Denmark; GloHAU, Centre for Global Health, School of Public Health, Aarhus University, Denmark.
Abstract
OBJECTIVES: To estimate the prevalence and determine the clinical presentation of risk factors of hepatitis C virus (HCV) among HIV-infected patients in Bissau, Guinea-Bissau. METHODS: In this cross-sectional study, we included individuals who had a routine blood analysis performed during the period April 28 to September 30, 2011. Patient samples were tested for HCV antibodies (anti-HCV) with a chemiluminescence test (Architect, Abbott, USA) and INNO-LIA HCV Score (Innogenetics, Belgium). HCV viral load and genotype were analyzed using an in-house real-time PCR method. RESULTS: In total, 576 patients were included (417 HIV-1, 104 HIV-2, and 55 HIV-1/2). Ten (1.7%) patients were anti-HCV-positive and eight (1.4%) patients had detectable HCV RNA; all were genotype 2. In a multivariable logistic regression analysis, age >50 years was associated with anti-HCV reactivity (p<0.01). No subjective symptoms or objective signs were more prevalent among patients with detectable HCV RNA compared to patients without detectable HCV RNA. Biochemically, detectable HCV RNA was associated with elevated amylase (83.3% vs. 38.6%, p=0.03), but not with the liver enzymes alanine aminotransferase and aspartate aminotransferase. CONCLUSIONS: The prevalence of anti-HCV was low and comparable to similar settings, and genotype analysis confirmed the presence of genotype 2 in West Africa.
OBJECTIVES: To estimate the prevalence and determine the clinical presentation of risk factors of hepatitis C virus (HCV) among HIV-infectedpatients in Bissau, Guinea-Bissau. METHODS: In this cross-sectional study, we included individuals who had a routine blood analysis performed during the period April 28 to September 30, 2011. Patient samples were tested for HCV antibodies (anti-HCV) with a chemiluminescence test (Architect, Abbott, USA) and INNO-LIA HCV Score (Innogenetics, Belgium). HCV viral load and genotype were analyzed using an in-house real-time PCR method. RESULTS: In total, 576 patients were included (417 HIV-1, 104 HIV-2, and 55 HIV-1/2). Ten (1.7%) patients were anti-HCV-positive and eight (1.4%) patients had detectable HCV RNA; all were genotype 2. In a multivariable logistic regression analysis, age >50 years was associated with anti-HCV reactivity (p<0.01). No subjective symptoms or objective signs were more prevalent among patients with detectable HCV RNA compared to patients without detectable HCV RNA. Biochemically, detectable HCV RNA was associated with elevated amylase (83.3% vs. 38.6%, p=0.03), but not with the liver enzymes alanine aminotransferase and aspartate aminotransferase. CONCLUSIONS: The prevalence of anti-HCV was low and comparable to similar settings, and genotype analysis confirmed the presence of genotype 2 in West Africa.
Authors: Bankole H Oladeinde; Ifeoma M Ekejindu; Richard Omoregie; Ikpomwonosa Odia; Obiora D Aguh; Uchechukwu M Okwu Journal: Int J Health Sci (Qassim) Date: 2018 Nov-Dec
Authors: Joakim Esbjörnsson; Marianne Jansson; Sanne Jespersen; Fredrik Månsson; Bo L Hønge; Jacob Lindman; Candida Medina; Zacarias J da Silva; Hans Norrgren; Patrik Medstrand; Sarah L Rowland-Jones; Christian Wejse Journal: AIDS Res Ther Date: 2019-09-05 Impact factor: 2.250
Authors: Didier K Ekouevi; Patrick A Coffie; Boris K Tchounga; Armel Poda; Antoine Jaquet; François Dabis; Serge P Eholie Journal: J Public Health Afr Date: 2018-10-10
Authors: S Jespersen; F Månsson; J Lindman; C Wejse; C Medina; Z J da Silva; DdS Te; P Medstrand; J Esbjörnsson; B L Hønge Journal: AIDS Res Ther Date: 2020-02-04 Impact factor: 2.250
Authors: Duncan Ndegwa Maina; Andrew Kimanga Nyerere; Ruth Wambui Gicho; Joseph Maina Mwangi; Raphael Wekesa Lihana Journal: East Afr Health Res J Date: 2017-07-01